AbbVie announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to venetoclax for the treatment of chronic lymphocytic leukemia (CLL) in previously treated (relapsed/refractory) patients with the 17p deletion genetic mutation.

Venetoclax is an investigational inhibitor of the B-cell lymphoma-2 (BCL-2) protein, which prevents apoptosis of some cells, including lymphocytes.

RELATED: Acute Myeloid Leukemia Therapy Granted Fast Track Status

Currently venetoclax is being evaluated in Phase 2 and Phase 3 clinical trials for the treatment of CLL, along with studies in several other cancers such as small lymphocytic lymphoma (SLL), non-Hodgkin’s lymphoma, multiple myeloma and acute myelogenous leukemia (AML).

For more information call (800) 633-9110 or visit AbbVie.com.